Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Citruslabs | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a single-arm, 12-week pilot study evaluating the effects of a chickpea pasta on gut microbiome diversity, gastrointestinal health, and blood biomarkers. The study will involve 12 participants consuming the test product five times per week, with questionnaires, microbiome testing, blood testing, and waist measurements collected at defined timepoints.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chickpea Pasta Intervention Arm | Experimental | Participants will consume 1½ cups (188g) of cooked Banza chickpea pasta once daily, 5 days per week, for 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chickpea Pasta | Dietary Supplement | The intervention is intended to assess the effects of a high-fiber, legume-based dietary product on gut microbiome diversity, gastrointestinal function, and metabolic biomarkers. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in gut microbiome diversity | Gut microbiome diversity will be assessed using microbiome testing of stool samples. This outcome will evaluate the effect of the intervention on microbial community richness and composition. | Baseline and Week 12 |
| Change in gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS) | Assessed using the GSRS to evaluate symptoms such as bloating and abdominal discomfort. | Baseline, Week 4, Week 8, and Week 12 |
| Change in blood biomarkers regarding Hemoglobin A1C | Measured via blood tests including Hemoglobin A1C with eAG. | Baseline and Week 12 |
| Change in blood biomarkers regarding CMP-14 | Measured via blood tests including CMP-14, lipid panel, and serum iron to assess metabolic and cardiovascular health indicators. | Baseline and Week 12 |
| Change in stool quality using the Bristol Stool Scale (BSS) | Assessed using the BSS to evaluate stool consistency and form. | Baseline, Week 4, Week 8, and Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Participant-reported perceptions of gut and overall health | Evaluated through self-reported questionnaires on perceived gut health, weight management, bloating, confidence in clothes, and overall well-being. | Baseline, Week 4, Week 8, and Week 12 |
| Change in waist circumference |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Citruslabs | Las Vegas | Nevada | 89118 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will self-measure and report waist circumference to assess changes in central adiposity over the course of the intervention. |
| Baseline, Week 4, Week 8, and Week 12 |